Key Takeaway: Telomir Pharmaceuticals, Inc. (TELO) has released its Q2 quarterly results for 2026. The report is available in both PDF and DOCX formats. Further details regarding the financial performance and operational highlights are expected to be outlined in the report.
Price reaction · baseline $1.05 (2026-08-13 close) · hit after-hours · clean, no other TELO news in the window
day 0 close · peak
+3.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
7.3%
average across 3 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Zn-Telomir
Phase 1 · Triple-Negative Breast Cancer (TNBC)
Full Press Release Details
General form for quarterly reports under Section 13 or 15(d) (PDF) General form for quarterly reports under Section 13 or 15(d) (DOCX)
The post Q2 Quarterly results 2026 appeared first on Telomir Pharmaceuticals, Inc. (TELO) .
Frequently Asked Questions
What are the Q2 results for Telomir Pharmaceuticals?
The Q2 results for Telomir Pharmaceuticals, Inc. (TELO) have been released.
In what formats are the quarterly results available?
The quarterly results are available in both PDF and DOCX formats.